Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 3/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.46 |
| ▸ | HPN | P05981 | 2/20 | 0.46 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | F13A1 | P00488 | 2/20 | 0.42 |
| ▸ | TGM1 | P22735 | 2/20 | 0.42 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16653847 | 0.90 | TGM2 (0.60) | TGM2CTSLCTSBCTSKHSD11B1 | |
| SCHEMBL16664895 | 0.86 | TGM2 (0.55) | TGM2CTSLCTSBCTSKHSD11B1 | |
| SCHEMBL3313307 | 0.85 | HPN (0.56) | TGM2CTSLCTSBCTSKHSD11B1 | |
| SCHEMBL3313305 | 0.85 | HPN (0.56) | TGM2CTSLCTSBCTSKHSD11B1 | |
| SCHEMBL20041225 | 0.83 | TGM2 (0.54) | TGM2CTSLCTSBCTSKHSD11B1 | |
| SCHEMBL3316730 | 0.83 | CTSL (0.53) | TGM2CTSLCTSBCTSKHSD11B1 | |
| SCHEMBL3316725 | 0.83 | CTSL (0.53) | TGM2CTSLCTSBCTSKHSD11B1 | |
| SCHEMBL3489847 | 0.78 | CTSL (0.62) | TGM2CTSLCTSBCTSKHSD11B1 | |
| SCHEMBL3313427 | 0.78 | USP30 (0.63) | CTSLCTSBCTSKHSD11B1DPP4 | |
| SCHEMBL21344371 | 0.78 | CTSL (0.54) | CTSLCTSBCTSKHSD11B1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040957-B2 | Heteroaromatic compounds useful for the treatment of proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190241541-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-08-08 | — | — | US | disclosed |
| EP-3057955-B1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20160264551-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241541-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK7, CDK3, CDK4 | TGM2 2738/4885CTSL 2400/4885CTSB 891/4885 |
| US-11040957-B2 | Heteroaromatic compounds useful for the treatment of proliferative diseases | CDK7, CDK3, CDK4 | TGM2 2738/4885CTSL 2400/4885CTSB 891/4885 |
| US-20160264551-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | CDK7, CDK6, CDK3 | TGM2 3308/4885CTSL 1219/4885CTSB 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.